ENVIVIO INC

CIK:0001174266|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 31, 2015	Jul. 31, 2014	Jul. 31, 2015	Jul. 31, 2014
Revenue:
Product	$ 8,933	$ 8,852	$ 15,652	$ 14,963
Professional services and support	2,752	2,600	5,546	4,903
Total revenue	11,685	11,452	21,198	19,866
Cost of revenue:
Product	2,784	4,077	4,477	6,128
Professional services and support	693	704	1,272	1,348
Total cost of revenue	3,477	4,781	5,749	7,476
Gross profit	8,208	6,671	15,449	12,390
Operating expenses:
Research and development	2,017	2,257	3,920	4,757
Sales and marketing	4,441	5,374	8,379	10,442
General and administrative	2,240	2,989	4,486	5,669
Total operating expenses	8,698	10,620	16,785	20,868
Loss from operations	(490)	(3,949)	(1,336)	(8,478)
Interest income, net	21	1	27	4
Other income (expense), net	48	(55)	(31)	(88)
Loss before provision for income taxes	(421)	(4,003)	(1,340)	(8,562)
Income tax provision	200	82	80	53
Net loss	$ (621)	$ (4,085)	$ (1,420)	$ (8,615)
Net loss per share of common stock, basic and diluted	$ (0.02)	$ (0.15)	$ (0.05)	$ (0.32)
Shares used in computing net loss per share of common stock, basic and diluted	27,725,755	27,496,793	27,721,425	27,322,736

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,420)	$ (8,615)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,105	1,358
Stock-based compensation	507	1,237
Bad debt expense	117	281
Loss on disposal of fixed assets	21	10
Changes in operating assets and liabilities:
Accounts receivable	(2,874)	(244)
Inventory	16	(151)
Prepaid expenses and other current assets	1,306	807
Deferred inventory costs	(405)	(297)
Other non-current assets	38	17
Accounts payable, accrued liabilities and accrued compensation	(1,624)	2,015
Deferred revenue	1,255	52
Other non-current liabilities and deferred rent	25	(64)
Net cash used in operating activities	(1,933)	(3,594)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(1,201)	(1,868)
Net cash used in investing activities	(1,201)	(1,868)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock options exercised	17	170
Repayment of French governmental research grant	(64)	(373)
Net cash used in financing activities	(47)	(203)
Effect of exchange rate changes on cash and cash equivalents	(75)	(76)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(3,256)	(5,741)
CASH AND CASH EQUIVALENTS - Beginning of period	37,790	47,873
CASH AND CASH EQUIVALENTS - End of period	34,534	42,132
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	1	0
Taxes paid	13	10
NON-CASH INVESTING AND FINANCING ACTIVITIES
Non-cash capital expenditures	$ 698	$ 0

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2015	Jan. 31, 2015
Current assets:
Cash and cash equivalents	$ 34,534	$ 37,790
Accounts receivable, net of allowance for doubtful accounts	11,536	8,780
Inventory	155	171
Prepaid expenses and other assets	2,349	3,655
Deferred inventory costs	491	86
Total current assets	49,065	50,482
Property and equipment, net	4,363	3,590
Restricted cash	329	329
Other non-current assets	164	202
Total assets	53,921	54,603
Current liabilities:
Accounts payable	6,113	5,480
Accrued compensation	4,558	5,070
Accrued liabilities	2,249	3,296
Deferred revenue, current	7,097	5,999
Total current liabilities	20,017	19,845
Deferred revenue, net of current portion	866	711
Other non-current liabilities	1,289	1,562
Deferred rent	733	498
Total liabilities	$ 22,905	$ 22,616
Stockholders' equity:
Preferred stock
Common stock	$ 28	$ 28
Additional paid-in capital	157,128	156,604
Accumulated other comprehensive loss	(1,154)	(1,079)
Accumulated deficit	(124,986)	(123,566)
Total stockholders' equity	31,016	31,987
Total liabilities and stockholders' equity	$ 53,921	$ 54,603